A primary challenge in the diagnosis of neurological disorders is differentiating between conditions that share clinical features. Absent of a clear diagnosis, proper
and effective patient care is hindered. Therefore, there is a great need for accessible diagnostic tools that help provide clarity to diagnosing clinicians.
CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $2.4 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA) of the National Institutes of Health (NIH).
Dr. Todd Levine, Chief Medical Officer and Co-Founder of CND Life Sciences will present as part of a Controversies in Movement Disorders panel discussion at 6:30 pm on May 23, 2022, in Punta Gorda, FL.
In honor of national Parkinson’s month, CN2 news in Rock Hill, SC featured Memory & Movement Charlotte, a medical practice focused on Parkinson’s disease and other neurological conditions, where Medical Director Dr. Sanjay Iyer has recently started offering the Syn-One Test to his patients.
Researchers from La Jolla Institute for Immunology have discovered a genetic signature on the circulating T cells of patients with Parkinson’s disease, which they hope can provide new avenues of research for potential treatments.
Will Advance the Company’s Technology Designed to Aid the Diagnosis of Parkinson’s Disease and Other Neurological Disorders
Strong market adoption of Syn-One Test™ to help clinicians diagnose Parkinson’s Disease and other neurological disorders
Vaxxinity, a “purpose-driven biotechnology company committed to democratizing healthcare across the globe,” announced that it has dosed its first patient with Parkinson’s disease in a Phase 1 study of the vaccine UB-312.
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded two grants to AC Immune, a Swiss-based biopharmaceutical company, to support the development of molecules designed to stop the accumulation of alpha-synuclein and inhibit an inflammatory pathway in Parkinson’s disease.
Boston- and Atlanta-based clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. published the biochemical rationale for potentially treating Parkinson’s disease with IkT-148009, a highly selective Abelson Tyrosine Kinase (c-Abl) inhibitor.